Literature DB >> 11698627

Hepatocellular carcinoma with blood supply from omental branches: treatment with transcatheter arterial embolization.

S Miyayama1, O Matsui, Y Akakura, T Yamamoto, H Nishida, K Yoneda, K Kawai, H Nishijima.   

Abstract

PURPOSE: To evaluate the usefulness of transcatheter arterial embolization (TAE) through the omental branch in the treatment of hepatocellular carcinoma (HCC) with blood supply from the omental branch.
MATERIALS AND METHODS: Fifteen patients with HCC fed by the omental branch underwent TAE. All but one had previously undergone several therapies for HCC, including TAE. Three patients had intraperitoneal hemorrhage caused by ruptured HCC fed by the omental branch, and two necessitated emergency TAE. The technical success rate, therapeutic effect, and safety of TAE via the omental branch were evaluated.
RESULTS: Twenty-six omental branches that fed HCC were observed angiographically. Attenuation or occlusion of the hepatic artery was observed in 80%. Nineteen omental branches (73%) could be successfully embolized. Hepatic hemostasis was achieved in all patients with ruptured HCC. Tumor recurred in 80% of patients who underwent successful TAE of the omental branch, and additional therapy was performed in six patients. Ten patients died after 2-26 months (mean, 8 mo). Five patients were alive for 3-13 months (mean, 7 mo). Severe complications were not observed in any patient.
CONCLUSION: TAE of the omental branch is safe and has become technically feasible in almost all patients, but tumors frequently recur.

Entities:  

Mesh:

Year:  2001        PMID: 11698627     DOI: 10.1016/s1051-0443(07)61553-x

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  8 in total

1.  Superior phrenic artery: an anatomic study.

Authors:  Marios Loukas; Robert G Louis; Christopher T Wartmann; R Shane Tubbs; Ehsan Esmaeili; Allyson C Bagenholm; William Merbs; Brian Curry; Robert Jordan
Journal:  Surg Radiol Anat       Date:  2006-12-20       Impact factor: 1.246

Review 2.  Variations in feeding arteries of hepatocellular carcinoma located in the left hepatic lobe.

Authors:  Shiro Miyayama; Masashi Yamashiro; Yoshihiro Shibata; Masahiro Hashimoto; Miki Yoshida; Kazunobu Tsuji; Fumihito Toshima; Osamu Matsui
Journal:  Jpn J Radiol       Date:  2012-04-03       Impact factor: 2.374

3.  Blood supply characteristics of pedunculated hepatocellular carcinoma prior to and following transcatheter arterial chemoembolization treatment: An angiographic demonstration.

Authors:  Dexiao Huang; Yong Chen; Qingle Zeng; Jianbo Zhao; Xizhong Wu; Renhua Wu; Yanhao Li
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

4.  Hepatocellular carcinoma with blood supply from parasitized omental artery: angiographic appearance and chemoembolization.

Authors:  Song Gao; Ren-Jie Yang; Jia-Hong Dong
Journal:  Chin J Cancer Res       Date:  2012-09       Impact factor: 5.087

5.  Transcatheter arterial chemoembolization of hepatocellular carcinoma: prevalence and causative factors of extrahepatic collateral arteries in 479 patients.

Authors:  Jin Wook Chung; Hyo-Cheol Kim; Jung-Hwan Yoon; Hyo-Suk Lee; Hwan Jun Jae; Whal Lee; Jae Hyung Park
Journal:  Korean J Radiol       Date:  2006 Oct-Dec       Impact factor: 3.500

6.  Transarterial embolization/chemoembolization therapy for hepatocellular carcinoma fed by adrenal artery: Preliminary results.

Authors:  Shibing Hu; Jianfei Tu; Zhongzhi Jia; Yuanquan Huang; Guomin Jiang
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

7.  Segmental Arterial Mediolysis of Omental Arteries with Haemoperitoneum: Case Report with Embolization of the Left Omental Artery and Brief Review of Literature.

Authors:  Gernot Rott; Frieder Boecker
Journal:  Case Rep Radiol       Date:  2018-07-18

Review 8.  Ruptured Hepatocellular Carcinoma: What Do Interventional Radiologists Need to Know?

Authors:  Jingxin Yan; Ting Li; Manjun Deng; Haining Fan
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.